RESUMEN
Graphene's two-dimensional structural arrangement has sparked a revolutionary transformation in the domain of conductive transparent devices, presenting a unique opportunity in the renewable energy sector. This comprehensive Review critically evaluates the most recent advances in graphene production and its employment in solar cells, focusing on dye-sensitized, organic, and perovskite devices for bulk heterojunction (BHJ) designs. This comprehensive investigation discovered the following captivating results: graphene integration resulted in a notable 20.3% improvement in energy conversion rates in graphene-perovskite photovoltaic cells. In comparison, BHJ cells saw a laudable 10% boost. Notably, graphene's 2D internal architecture emerges as a protector for photovoltaic devices, guaranteeing long-term stability against various environmental challenges. It acts as a transportation facilitator and charge extractor to the electrodes in photovoltaic cells. Additionally, this Review investigates current research highlighting the role of graphene derivatives and their products in solar PV systems, illuminating the way forward. The study elaborates on the complexities, challenges, and promising prospects underlying the use of graphene, revealing its reflective implications for the future of solar photovoltaic applications.
RESUMEN
A reduction-mediated technetium-99m labelling method has been evaluated with a range of tumour-specific monoclonal antibodies. Antibodies reduced with 2-mercaptoethanol (2-ME) had free sulphydryl groups, but their number was much higher than could be accounted for by only limited intra-chain reduction of disulphide bonds. Reduced antibody could be labelled efficiently with 99mTc using an methylene diphosphonate (MDP) bone-scanning kit, although this seemed to depend on the presence of residual 2-ME in the preparations. With a carcinoembryonic antigen (CEA)-specific antibody, immunoreactivity of labelled antibody was confirmed, and after injection into nude with CEA-producing xenografts there was localisation into the tumours. Sephacryl S300 gel filtration showed the radiolabel eluting at a single discrete peak at the expected 150 kDa. However, examination of all of the labelled antibodies by polyacrylamide gel electrophoresis (PAGE) and autoradiography showed the presence of a large number of radiolabelled low molecular weight degradation products of the antibodies. These degradation products seemed to be formed in previously reduced antibodies during processing for PAGE, indicating some fragility of the reduced antibody.